Lipid Lowering Therapy and Circulating PCSK9 Concentration.

about

Guidance for Pediatric Familial Hypercholesterolemia 2017.The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy.

P2860

Q50130465-673EF5A3-0891-4058-AC10-8F0375D77AFA Q55313083-ECD6F10D-0104-4706-B420-3A5D008E953E

P2860

Lipid Lowering Therapy and Circulating PCSK9 Concentration.

Item

http://www.wikidata.org/entity/Q38643197

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Lipid Lowering Therapy and Circulating PCSK9 Concentration.

@en

type

Item

label

Lipid Lowering Therapy and Circulating PCSK9 Concentration.

@en

prefLabel

Lipid Lowering Therapy and Circulating PCSK9 Concentration.

@en

P1476

Lipid Lowering Therapy and Circulating PCSK9 Concentration.

@en

P2093

Tsuyoshi Nozue

http://www.w3.org/2001/XMLSchema#string

P2860

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

Functional characterization of Narc 1, a novel proteinase related to proteinase K

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

The PCSK9 decade

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

PCSK9: a key modulator of cardiovascular health

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

P304

895-907

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.5551/JAT.RV17012

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28804094

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

dyslipidemias

Anzim

P932

5587514

http://www.w3.org/2001/XMLSchema#string

Lipid Lowering Therapy and Circulating PCSK9 Concentration.

about

P2860

P2860

Lipid Lowering Therapy and Circulating PCSK9 Concentration.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932